Archive for January 3rd, 2012

AVEO releases Phase 3 tivozanib RCC data. PARD delisted. BNVI cash raise + AEZS news

Jan 03, 2012 No Comments by

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Astellas Pharma Inc. today announced topline data from their Phase 3 trial of tivozanib compared with currently approved sorafenib, in patients with advanced renal cell carcinoma (RCC). Median overall Progression free survival (PFS) for patients treated with Tivozanib was 11.9 months compared to a median PFS of 9.1 months for sorafenib. In patients […]

Daily News Read more